Search results
p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing...
Nature· 5 days agoCancer stem cells (CSCs), which are distinct subpopulations of tumor cells, have a substantially higher tumor-initiating capacity and are closely related to poor clinical ...
Scientists create tailored drug for aggressive breast cancer
Medical Xpress· 4 days agoScientists have used breast cancer cells' weakness against themselves by linking a tumor-selective...
PKMYT1, a potential 'Achilles heel' of treatment resistant ER+ breast cancers with the poorest...
Medical Xpress· 1 day agoLooking to identify new vulnerabilities in this type of cancer that could lead to improved...
New customised drug developed to fight aggressive breast cancer
Investing.com· 4 days agoNew customised drug developed to fight aggressive breast cancer
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer
Nature· 2 days agoDiscover the world’s best science and medicine | Nature.com
Cedars-Sinai Experts Present Cancer News at ASCO A | Newswise
Newswise· 2 days agoCedars-Sinai Cancer physician-scientists and thought leaders will discuss scientific advances, new therapies, and the future of cancer care at the American
Tumor mutations may not predict response to immunotherapy, study finds
Medical Xpress· 2 days agoThe findings, published in Nature Cancer, upend long-held conventional wisdom and could lead to more effective ways of deciding which patients will benefit most from this ...
The price of hope: CAR-T therapy in pediatric leukemia
Medical Xpress· 5 days agoWe stand at the crossroads of medical innovation, where cutting-edge scientific discoveries...
Get Ready for ASCO 2024 Annual Meeting | Newswise
Newswise· 4 days agoASCO, the largest event in cancer research, is approaching on May 31st. This year's meeting promises to be particularly groundbreaking, with new findings a
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...